Compartment-Specific Focused Shockwave and Extracorporeal Magnetotransduction Therapy Followed by Platelet-Rich Plasma and Hyaluronic Acid for Lateral Knee Osteoarthritis with Medial Bone Marrow Lesion and Meniscus Tear: A Case Report

Technical Summary: Compartment-Specific Focused Shockwave and EMTT Followed by PRP and HA for Complex Knee Osteoarthritis

Problem Statement
This case report addresses the clinical challenge of managing complex knee pathology where multiple degenerative conditions coexist and interact mechanically and biologically. The specific case involves a 77-year-old male presenting with a triad of pathologies: severe lateral compartment osteoarthritis (Kellgren-Lawrence grade 4), a large degenerative medial meniscus tear, and a medial femoral condyle bone marrow lesion (BML). The authors note that these conditions are not incidental but mutually reinforcing; meniscal tears alter load distribution, leading to focal overload and subsequent BMLs, which are independent predictors of pain and structural progression. A key practical problem identified is whether a single treatment protocol can address pathology distributed across two distinct tibiofemoral compartments (lateral arthritis vs. medial bone/meniscus pathology) or if each compartment requires compartment-specific, independently titrated dosing.

Methodology
The study describes a staged, non-surgical, multimodal protocol implemented over a 6-week period for a single patient. The treatment was divided into three phases:

1. Mechanotransductive Priming (Days 4–24): The patient underwent seven sessions of focused extracorporeal shockwave therapy (ESWT) and extracorporeal magnetotransduction therapy (EMTT).

   • Compartment-Specific Dosing: Unlike standard protocols treating the knee as a single unit, the lateral and medial compartments were treated as distinct sites with independent energy titration.
     • Lateral Site (Osteoarthritis): Treated with higher energy flux densities (ranging from 0.10 to 0.25 mJ/mm²) using an S2 applicator.
     • Medial Site (BML/Meniscus): Treated with significantly lower energy (0.05 to 0.07 mJ/mm²), utilizing an S2 applicator initially and switching to an S1 applicator from Day 15 onward.
   • EMTT Parameters: Applied uniformly to both sites at Level 8 intensity, 8 Hz frequency, and 6,000 pulses per site per session.
   • No Anesthesia: All sessions were performed without local anesthesia.

2. Biologic and Viscosupplement Injection (Day 24): Immediately following the seventh ESWT/EMTT session, the patient received ultrasound-guided intra-articular injections of:

   • Leukocyte-poor Platelet-Rich Plasma (LP-PRP): Prepared from 80 mL of peripheral blood, injected as 2.75 mL LP-PRP mixed with 0.5 mL sodium bicarbonate, plus 2.75 mL platelet-poor plasma (PPP) with 0.25 mL sodium bicarbonate.
   • Hyaluronic Acid (HA): 3 mL of high molecular weight, stabilized non-animal HA (Durolane, 60 mg/3 mL).

3. Rehabilitation and Follow-up: The patient was kept partial weight-bearing for 3 days post-injection. Formal physical therapy commenced 3 weeks post-injection. Outcomes were tracked using the Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS Jr.)—specifically Symptoms, Pain, and Quality of Life (QOL) subscores—and the Numerical Rating Scale (NRS) for pain.

Key Results
The patient demonstrated substantial functional improvement by the 6-week follow-up, though the trajectory was non-linear:

• Baseline: KOOS Jr. Pain (61.11), Symptoms (57.14), QOL (43.75); NRS 5/10.
• Priming Phase (Days 4–21): Early improvement was observed, with QOL peaking at 62.50 by Treatment 3. However, this gain was not sustained; by Treatment 6, QOL regressed to baseline (43.75), and NRS pain increased from 2/10 to 3/10.
• Post-Injection Phase (Day 24 onwards): Following the PRP/HA injection, the recovery trajectory resumed.
  • 10-day follow-up: NRS dropped to 1/10; QOL improved to 56.25.
  • 6-week follow-up: The patient achieved the best outcomes of the course:
    • Pain: 88.89 (up from 61.11).
    • Symptoms: 85.71 (up from 57.14).
    • QOL: 75.00 (up from 43.75).
    • NRS: 1/10.
• Safety: No adverse events were reported. The patient tolerated all ESWT/EMTT sessions without anesthesia and experienced no injection-related complications.

Significance and Claims
The authors frame this case as a hypothesis-generating report rather than a confirmation of efficacy. The primary significance claimed is the demonstration of a compartment-specific dosing strategy, where the lateral arthritic compartment and the medial bone marrow lesion were treated with distinct energy levels (lateral receiving roughly 3–5 times the energy of the medial site). This approach challenges the notion of treating the knee as a monolithic target and suggests that subchondral BMLs may be active, treatable contributors to pain requiring specific, lower-dose mechanotransductive intervention.

The paper explicitly acknowledges limitations:

• Attribution: The relative contribution of individual modalities (ESWT, EMTT, PRP, HA) cannot be isolated; the results reflect the combined protocol.
• Duration: The 6-week follow-up is insufficient to determine the durability of the effect or to assess structural changes in the bone marrow lesion. The peak result at 6 weeks may coincide with the known peak effect window of hyaluronic acid viscosupplementation.
• Generalizability: As a single case report, the findings cannot establish causality or generalizability, particularly given the patient's unique presentation of lateral arthritis despite a longstanding varus deformity (which typically correlates with medial pathology).

The authors conclude that while the combined protocol yielded substantial symptomatic improvement, controlled, adequately powered studies with longer follow-up are required to validate this approach for patients with overlapping compartment osteoarthritis, bone marrow lesions, and meniscus pathology.